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Bone mineral metabolismAbstract Background: Pain is one of the most common complaints in clinical practice because it is
a symptom for a myriad of physical and mental problems. The high prevalence of pain in the
chronic kidney disease (CKD) population is particularly concerning because pain has been shown
to adversely affect quality of life. The aim of this study was to evaluate the prevalence and possible
causes of chronic pain in patients with end stage renal disease on long-term hemodialysis (HD).
Methods: We prospectively enrolled 100 patients who were undergoing maintenance HD for at
least 6 months or more. Pain was evaluated using the Brief Pain Inventory (BPI). Data collected
on each participant included age, gender, body mass index (BMI), time on dialysis and biochemical
findings.
Results: The average age was 42.06 years ranged from 22 to 58 years; the average duration on dial-
ysis was 4.97 years. 52 patients were males and 48 were females. Although 52% of patients experi-
enced chronic pain, only 25% described the pain as severe, 28% described pain as moderate while
52% of patients described as mild. Musculoskeletal pain was the most frequent form of chronic
pain reported by patients who were on HD (54%). Malnutrition and high CRP were highly statis-
tically associated with chronic pain (p< 0.001). High statistical significant correlation was found
between lower calcium, lower 25(OH) D3 levels, higher parathyroid hormone (PTH) levels and
experienced chronic pain (p< 0.001).
Conclusion: Chronic pain is highly experienced in long-term hemodialysis patients. Malnutrition,
high CRP and disturbed bone mineral metabolism are highly correlated with the incident of this
pain.
 2015 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pain is a frequent complaint of hemodialysis (HD) patients.1,2
The information regarding its origins, frequency, and manage-
ment is relatively scarce. Most published data come indirectly
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reported frequency of pain varies widely in these patients.
Murtagh et al.,3 in a review of symptoms in ESRD, reported
that the mean prevalence of pain is of 47%, with a range of
8–82%. The International Association for the Study of Pain
(IASP) has defined pain as ‘‘an unpleasant sensory and emo-
tional experience associated with an actual or potential harm
to the body”.4 In most patients, severity of pain ranges from
moderate to severe.5 Important sources of pain are muscu-
loskeletal disorders, peripheral neuropathy and critical limb
ischemia. Moreover renal replacement therapy with hemodial-
ysis or peritoneal dialysis is associated with additional pain
manifestations.6,7 Three quarters of ESRD patients suffer
unnecessarily from inadequately or untreated pain.1,5 In the
Dialysis Outcomes and Practice Patterns Study (DOPPS),
74% of subjects reported a moderate to severe pain without
analgesic prescription.8 These hurdles are due to several fac-
tors: The caregivers are frequently unaware of this problem
and have concerns about adverse effects of the analgesic ther-
apy, and the patients fear the side effects of medication, the
extra burden of daily tablets and the potential risk of addiction
in the case of opiate medication.9 Although well-accepted
guidelines are available for the management of cancer-related
pain, no such recommendations exist for pain associated with
HD.10 One review11 suggested using the same step-wise
approach declared by the World Health Organization to treat
cancer pain; however, the treatment of HD patients is compli-
cated by the need to adjust frequently the dosage of analgesic
drugs and by increased risk for adverse effects.12,13 because of
the high prevalence and adverse effects of this complaint, and
we designed this study aiming to evaluate its incidence and
characters of distribution in our hemodialysis community
and trying to find out the major determinants of this very
common complaint.
2. Patients and methods
This prospective cross-sectional study was carried out in the
internal medicine department and renal unit, Zagazig univer-
sity hospital, Egypt. One hundred eligible patients who had
been undergoing maintenance HD for at least 6 months were
recruited for this study. They were followed for one year (from
December 2013 to December 2014). Informed written consent
was taken from all participants and then they were randomly
selected and interviewed during dialysis sessions. They were
divided according to the presence or absence of chronic pain
into two groups: Group 1: it included 48 patients. They were
25 males and 23 females, with age range from 22 to 50 years
(mean ± SD: 42.12 ± 10.32 years). They were treated with a
regular HD for P6 months and they did not experience
chronic pain. Group 2: it included 52 patients. They were 28
males and 24 females, with an age range from 21 to 58 years,
(mean ± SD: 42.06 ± 10.26 years). They were treated with a
regular HD for P6 months and they were complaining from
different types of chronic pain.
Inclusion criteria: All patients who were free from diabetes
mellitus (DM), connective tissue diseases, heart failure, liver
diseases or evident acute infection and were not receiving
medications that may modify pain or the immune response
like non-steroidal anti-inflammatory medications or corticos-
teroids were included in the study.Exclusion criteria: Patients with central venous catheters
and Arteriovenous fistula (AVF) that were prone to limb
ischemic pain were excluded from the study. Also, patients
with recurrent pain due to needling, headaches and muscle
cramps during the HD procedure were excluded as these con-
ditions may be perceived as a chronic pain and so can affect
the results of our study. Our patients were free of cancer for
the last 2 years prior to the study.
They were treated thrice weekly HD sessions for 4 h dura-
tion using volumetric machines and high-flux polysulphone
membrane (Haidylena Medical SAE, Cairo, Egypt). The dialy-
sate flow was 500 mL/min and the blood flow rate ranged from
270 to 350 mL/min. We used standard bicarbonate dialysate
(38 mEq/l) with normal calcium bath of 1.25 mmo/l.
Demographic and clinical data were collected for all
patients. Demographic data included complete history taking,
age, gender, body mass index (BMI), nutritional status, time
on dialysis and the type of blood access. Clinical data included
the following: complete blood count (CBC), serum calcium,
phosphorus, uric acid, intact parathyroid hormone (iPTH by
immunoradiometric assay (N-TACT PTH SP IRMA; Dia-
Sorin), 25-hydroxyvitamin D3 [25(OH)D3] by Elisa, serum
albumin, alanine transaminase (ALT), aspartate transaminase
(AST), and C-reactive protein (CRP). Also, we determined
serum low-density lipoprotein (LDL), serum high-density
lipoprotein (HDL) and triglyceride (TG), and single pool
Kt/V using Daugirdas formula.14
A Hitachi747 Clinical Analyzer was used to determine the
serum levels of albumin, glucose, iron, calcium, and phosphorus.
A Hitachi 917 was used for C-reactive protein, and Advia 120
(Bayer, Leverkusen, Germany) was used to determine hemoglo-
bin levels. Serum total cholesterol (TC), triglycerides (TGs),
HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C), were
measured calorimetrically using commercially available kits on
the fully auto analyzer of Clinical Biochemistry Laboratory
2.1. Pain assessment (brief pain inventory score)
All patients were interviewed during their HD session evalu-
ated for the presence of pain by using the Brief Pain Inventory
(BPI)15 which is an instrument for evaluating pain that assesses
the intensity and characteristics of pain and determines the
impact of pain on important aspects of a patient’s life. The
BPI uses a 10-point scale to evaluate the intensity of pain
whereby 0 = ‘‘no pain” and 10 = severe pain.15 On the basis
of the BPI scale, pain was classified as mild (1–4 points), mod-
erate (5–6 points), or severe (7–10 points).17 Chronic pain was
defined as pain of >3 months duration.17
2.2. Dialysis malnutrition score
Assessment of the nutritional status uses Modified Subjective
Global Assessment – Dialysis Malnutrition Score which con-
sists of seven features: weight change, dietary intake, GI symp-
toms, functional capacity, comorbidity, subcutaneous fat and
signs of muscle wasting. Each component has a score from 1
(normal) to 5 (very severe). Thus the malnutrition score (sum
of all seven components) is a number between 7 (normal) and
35 (severely malnourished). Lower score denotes tendency
toward a normal nutritional status. A higher score is considered
to be an indicator of the presence of malnutrition elements i.e.
protein energy malnutrition.16
Table 1 Demographic characteristics and laboratory values of studied HD groups.
Variable Group I
Pain free (n= 48)
Group II
Complaining from pain (n= 52)
t P
Age (year)
X ± SD
42.12 ± 10.32 42.06 ± 10.26 0. 02 NS
Gender (%)
Male 25 28 0.59 NS
Female 23 24
BMI (kg/m2)
X ± SD
19.95 ± 1.84 19.35 ± 1.49 1.79 NS
Duration (years)
X ± SD
5.11 ± 2.16 4.97 ± 1.82 0.34 NS
CRP (mg/dl)
X ± SD
3.37 ± 1.40 8.13 ± 2.75 10.89 <0.001
Hb (Gm/dl)
X ± SD
10.60 ± 0.79 10.58 ± 0.76 0.11 NS
Uric acid (mg/dl)
X ± SD
5.73 ± 1.32 5.96 ± 1.33 0.86 NS
Kt/V
X± SD
1.33 ± 0.22 1.41 ± 0.27 0.56 NS
Na+2 (mEq/l)
X ± SD
137.6 ± 7.23 138.4 ± 6.73 0.57 NS
K+ (mEq/l)
X ± SD
4.61 ± 0.57 4.79 ± 0.52 4.41 NS
SGA
X± SD
8.84 ± 2.24 18.22 ± 8.48 7.55 <0.001
Albumin (g/dl)
X ± SD
3.61 ± 0.64 3.51 ± 0.68 0.02 NS
ALT Mg/dl
X ± SD
30 ± 7.88 31.3 ± 6.98 4.41 NS
AST Mg/dl
X ± SD
29 ± 6.98 30.9 ± 6.97 4.13 NS
LDL Mg/dl
X ± SD
108.3 ± 13.15 116 ± 14.35 2.79 <0.05
HDL mg/dL
X± SD
45 ± 2.97 36.78 ± 4.25 11.21 <0.001
TG mg/dL
X± SD
195.9 ± 24.55 262.9 ± 45.18 9.21 <0.001
BMI: body mass index, CRP: C-reactive protein, Hb: hemoglobin, Cr: Creatinine, Na: Sodium, K: potassium, SGA: modified subjective global
assessment, ALT: alanine transaminase, AST: aspartate transaminase, LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG:
triglyceride.
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Data collected throughout history, basic clinical examination,
laboratory investigations and outcome measures were coded,
entered and analyzed using Microsoft Excel software. Data
were then imported into the statistical package for the social
sciences (SPSS version 20.0) software for analysis. Continuous
variables are presented as mean ± SD or median and range.
The Chi-square test was used for qualitative data (frequency
and proportion), independent t-test was used to compare 2
groups and one-way ANOVA test was used to compare more
than 2 groups. Statistical significance was set at 5% (P< 0.05).3. Results
Table 1 summarizes the basic demographic characteristics and
laboratory values of the studied groups. On analysis of the
demographic data, it was found that there was no significant
difference between both groups regarding age, gender, BMI,duration of dialysis and dialysis adequacy (Kt/v) p> 0.05.
However, on Analysis of the laboratory parameters it was
revealed that there was no significant difference found between
the two groups regarding hemoglobin, uric acid, serum sodium
and potassium (p> 0.05). CRP was significantly higher in pain
group than in non-pain group (p< 0.001). Regarding the
nutritional status of both groups, although there was no signif-
icant difference between both groups regarding serum albumin
(p> 0.05), Malnutrition was highly significant higher in
group 2 (pain group) in comparison with the other group
using our modified subjective global assessment score (SGA)
(p< 0.001). Liver enzymes (ALT and AST) did not show any
significant changes in both groups of patients (p> 0.05).
Dyslipidemia in the form of high LDL, low HDL and high
triglycerides was significantly higher in group 2 (pain group)
than the other free group (group 1) (p< 0.05, <0.001 and
<0.001 respectively).
Regarding bone mineral study in both groups, parathyroid
hormone was statistically significantly higher in patients with
pain in comparison with other patients without pain
Table 2 Bone minerals in both groups.
Variable Group I
Pain free (n= 48)
Group II
Complaining from pain (n= 52)
t P
Ca (mg/dl)
X ± SD
9.99 ± .34 7.77 ± .45 9.73 <0.001
Ph (mg/dl)
X ± SD
5.41 ± .65 5.42 ± .63 .11 NS
PTH (pg/ml)
X ± SD
219 ± 68 775 ± 270 14.09 <0.001
OHD3 (nmol/L)
X ± SD
73.34 ± 23.18 40.3 ± 13.48 6.03 <0.001
NS: non-significant p> 0.05, Ca: Calcium, Ph: phosphorus, PTH: parathyroid hormones, OHD3: 25-hydroxyvitamin D3.
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patients with pain in comparison with those without pain
p< 0.001. Also, serum: 25-hydroxyvitamin D3 was highly sig-
nificantly lower in patients with pain in comparison with
patients without pain (p< 0.001). However, no significant dif-
ference was found between both groups regarding serum phos-
phorus level p> 0.05. See Table 2.
Regarding grades of pain in group 2, 52% of patients had
mild pain (grade 2), 28% of patients had moderate pain (grade
3) and 20% of patients had severe pain (grade 4). 27 patients
of the 52 patients (52%) who had pain reportedmusculoskeletal
pain, 12 patients reported headache (23%), 7 patients reported
peripheral neuropathic pain (13.5%), 3 patients reportedTable 3 Comparison of pain grades in relation to socio-demograph
from pain.
Variable Pain grades
Grade 2 (n= 26) Grade 3 (n=
Age (year)
X ± SD
36.11 ± 8.59 45.42 ± 8.5
BMI (kg/m2)
X ± SD
19.9 ± 1.1 19.42 ± 1.59
Duration (years)
X ± SD
4.0 ± 1.13 4.96 ± 1.56
Hb (Gm/dl)
X ± SD
10.82 ± 0.79 10.26 ± 0.708
Ca (mg/dl)
X ± SD
7.71 ± 0.45 7.77 ± 0.45
Ph (mg/dl)
X ± SD
5.40 ± 0.57 5.53 ± 0.78
iPTH (pg/ml)
X ± SD
744.23 ± 218.2 655.0 ± 234.5
OHD3
(nmol/L) X ± SD
42.88 ± 23.54 37.86 ± 30.55
Albumin (g/dl)
X ± SD
3.87 ± 0.38 3.39 ± 0.83
ALT (mg/dl)
X ± SD
35.76 ± 5.77 36.42 ± 8.41
AST (mg/dl)
X ± SD
30.38 ± 6.31 30.71 ± 7.55
Uric acid
(mg/dl) X ± SD
9.12 ± 1.64 6.46 ± 1.43
NS: non-significant p> 0.05, Hb: hemoglobin, Ca: calcium, Ph: Phospho
D3, ALT: alanine aminotransferase, AST: aspartate aminotransferase.abdominal pain (5.7%) and 3 other patients reported pain of dif-
ferent sources (5.7%). Moreover, 36 (69.2%) patients reported
more than one type of pain.
Pain grade was significantly more pronounced in older age
groups and in patients with more time on hemodialysis
(p< 0.001). Moreover, it was less in patients with more BMI
(p< 0.001). The grades of pain were significantly increased in
patients with higher PTH and patients with low albumin level
(p< 0.001). However, no significant difference was found
between the pain grades in relation to hemoglobin (HB), cal-
cium, phosphorus, 25-hydroxyvitamin D3(OHD3), alanine
aminotransferase (ALT), aspartate aminotransferase (AST)
and uric acid (p> 0.05). See Table 3.ic characteristics and clinical Parameters of group II complaining
F P value
14) Grade 4 (n= 12)
52.8 ± 3.93 17.9 0.001
17.8 ± 1.22 9.78 0.001
7.5 ± 1.08 28.0 0.001
10.42 ± 0.594 2.91 0.06
7.93 ± 0.47 0.76 0.47
5.33 ± 0.61 0.32 0.72
1024 ± 305.14 7.24 0.001
37.5 ± 24.3 0.2 0.7
2.7 ± 0.25 16.94 0.001
37.5 ± 8.24 0.21 0.81
32.5 ± 8.24 0.33 0.72
6.25 ± 1.39 2.45 0.09
rus, iPTH: intact parathyroid hormones, OHD3: 25-hydroxyvitamin
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Patients with end-stage renal disease (ESRD) receiving mainte-
nance dialysis suffer from a multitude of physical and emo-
tional symptoms, exhibit a particularly high prevalence of
pain, and experience substantial impairments in quality of life
(QoL).18 Moreover, as many as 50% of patients suffer from
pain, which in longitudinal analysis has been associated with
an increased risk of death.19 Our study showed that pain is
common in patients who are on long-term HD and 52% of
our patients experienced chronic pain. This is in agreement
with other reports in the literature. Davison SN in 20031 on
his study on 205 Canadian HD patients reported that 50%
of patients had chronic pain. In a systematic review of
Murtagh et al.3 they reported that weighted mean prevalence
of pain was 47% but with a range from 8% to 82%. This wide
range is probably due to differences in the definition of chronic
pain and the method used to assess it, as well as differences in
the perception of pain among the diverse population studied.
52% of our patients who had chronic pain reported mild
pain (grade 2), 28% of patients had moderate pain (grade 3)
and only 20% of patients had severe pain (grade 4). In the
study done by Davison SN in 2003,1 he reported that 55%
of patients rated their pain as severe. In another study done
by Eliezer et al.,18 he reported that 49% of patients described
their pain as mild, 31.4% as moderate, and 19.6% as severe.
Differences in the perception of pain between our study and
the others may be explained by the cultural and ethnic varia-
tions. Kimmel et al.,20 described similar differences in HD
patients in Taiwan while discussing the impact of spiritual
beliefs, psychosocial factors, and ethnicity on QoL and HD.
No significant difference was found between age, sex, BMI
and pain in hemodialysis patients. Also, highly statistical sig-
nificant difference was found between C-reactive protein
(CRP) and chronic pain in hemodialysis patients. This result
is in accordance with the result of other studies.18 CRP is an
acute-phase reactant and it is a sensitive and independent mar-
ker of malnutrition, anemia, and amyloidosis which have pos-
sible roles in increasing perception of chronic pain in
hemodialysis patients.21
In contrast to other studies,22 no significant difference was
found between Hemoglobin level and chronic pain in
hemodialysis patients. However, similar result was found in
the study done by Eliezeret al.18 This is most probably because
the hemoglobin level of most of our patients was within the
recommended range due to better control of anemia.
In our study, high statistical significant difference was
found between malnutrition and pain through using modified
Subjective Global Assessment (SGA) – Dialysis malnutrition
score. Vasantha et al.,23 stated that malnutrition is widely
prevalent among patients on hemodialysis. Malnutrition is a
frequent complication which affects QoL and is associated
with increased risk of mortality and morbidity in maintenance
hemodialysis patients as it leads to osteoporosis, muscle weak-
ness, atherosclerosis and elevation of low density of lipopro-
tein (LDL) cholesterol which cause chronic ischemic pain.
Also in this study, it was found that iPTH was highly
statistically significant higher in pain group together with
low calcium and low 25-hydroxyvitamin D3. This is in agree-
ment with other reports who reported the same results but in
diabetic patients.24,25 Also, it is in accordance with other studydone by Rengin et al.,26 who reported that chronic pain is cor-
related with bone metabolism markers, namely intact parathy-
roid hormone, and may be used to assess the intensity of
chronic bone pain in long-term HD patients. However, in
the study done by Eliezeret al.,18 they reported that the levels
of intact parathyroid hormone, calcium, and calcitriol (but
not 25-hydroxyvitamin D3) differed significantly between
those who experienced chronic pain and those who did not.
Low calcium and vitamin D are associated with endothelial
dysfunction.27 Lower levels of calcium and 25-hydroxyvitamin
D3 observed in our patients may play a role in the develop-
ment of chronic ischemic pain in various organs by their
impact on endothelial dysfunction. Analysis of data from the
prospective Netherlands Cooperative Study on the Adequacy
of Dialysis (NECOSAD) reported that disturbed mineral
metabolism was associated with muscle pain and cramps in
dialysis patient.28 In our study, there was no statistical signif-
icant effect of phosphorus level on pain. This is in contradic-
tion to another study done by Noordzijet al.,28 who
described a positive correlation between phosphorus levels
and pain in hemodialysis patients. This difference in the result
may come from the tight control of phosphorus in almost all of
our patients, both with and without pain. Also, it can be
explained by different estimates of pain and from the different
study design, longitudinal versus case-control trials.5. Conclusion
Our work points out the likelihood that disturbed mineral
metabolism, especially calcium, PTH, and 25(OH) D3 has a
strong association with chronic pain experienced by HD
patients and causes psychological, physical, emotional and
social problems. Further studies on more patients may be
required to confirm this relationship for better diagnosis and
management of chronic pain in HD patients.
5.1. Limitations
This study has some limitations; first, it was designed as a
cross-sectional study but with almost equal sized groups and
almost equal gender distribution so it can be misleading as a
case control study. Also, it contributes to small numbers of
participant and this may preclude drawing firm cause-and-
effect conclusions from our data.
Second, we couldn’t obtain information about the use of
certain drugs that can affect parameters of bone mineral meta-
bolism like using of phosphate binders (calcium carbonate or
sevelamer hydrochloride), active vitamin D3 (Calcitriol) and
calcimimetics (cinacalcet). Third, it was better to do Logistic
Regression Analysis to Determine Factors Associated with
chronic pain in long-term HD patients.Conflict of interest
None.
Disclosure of grants or other funding
None.
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